SA
Go ProLog In
ADVM
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
15 analysts·Moderate coverage
67
Score
10 Buy (67%)5 Hold (33%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
1067%
Hold
533%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$2.00
-54.1%
Consensus
$5.00
+14.7%
Bull
$28.00
+542.2%
12-Month Target Range15 analysts
$2.00$5.00$28.00
Current $4.36Consensus
Current Price
$4.36
Upside to Consensus
$0.64

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

No analyst estimates available

Earnings Surprises

Earnings surprise history unavailable.

Recent Analyst Actions

Oct 29, 2025Mizuho Securities
Adverum Biotechnologies price target lowered to $5.50 from $12 at Mizuho
Target:$5.50
+30.3%from $4.22
Oct 28, 2025RBC Capital
Adverum Biotechnologies price target raised to $4 from $3 at RBC Capital
Target:$4.00
-5.5%from $4.24
Oct 24, 2025Truist Financial
Adverum Biotechnologies downgraded to Hold from Buy at Truist
Target:$5.00
+22.9%from $4.07
Nov 5, 2024RBC Capital
Adverum Biotechnologies (ADVM) PT Lowered to $10 at RBC Capital
Target:$10.00
+29.5%from $7.72
Oct 14, 2024Oppenheimer
Oppenheimer Reiterates Outperform Rating on Adverum Biotechnologies (ADVM)
Target:$28.00
+258.5%from $7.81
Sep 20, 2024Mizuho Securities
Mizuho Reiterates Outperform Rating on Adverum Biotechnologies (ADVM)
Target:$20.00
+166.7%from $7.50
Aug 13, 2024RBC Capital
Adverum Biotechnologies price target lowered to $12 from $15 at RBC Capital
Target:$12.00
+80.7%from $6.64
Nov 11, 2022Chardan Capital
Chardan Capital Maintains Neutral on Adverum Biotechnologies, Lowers Price Target to $2
Target:$2.00
+183.6%from $0.71

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance